The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | ImmunoPRISM results: teclistamab improves depth of response and PFS compared with Rd in HR-SMM
In this interview, Omar Nadeem, MD, Dana-Farber Cancer Institute, Boston, MA, presents findings from the Phase II ImmunoPRISM trial (NCT05469893), which evaluated the efficacy and safety of teclistamab compared with lenalidomide and dexamethasone (Rd) in patients with high-risk smoldering multiple myeloma (HR-SMM). Teclistamab demonstrated a favorable toxicity profile and improved the complete response (CR) rate, progression-free survival (PFS), and measurable residual disease (MRD) negativity rates compared with the control arm, suggesting that this BCMA-targeted bispecific therapy may provide a potential treatment option for patients with HR-SMM. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
